VALNEVA: Valneva Reports Full Year 2022 Results and Provides Corporate Updates : vimarsana.com

Total revenues of €361.3 million in 2022 compared to €348.1 million in 2021 Driven by product sales of €114.8 million (82.3% increase compared to 2021), including €85.2 million of travel vaccine sales

Related Keywords

Japan , Finland , Australia , Thailand , France , New Zealand , Sweden , United Kingdom , United Arab Emirates , Denmark , Austria , Germany , Bulgaria , United States , Brazil , Bahrain , Canada , Switzerland , America , Scotland , Kingdom Of Bahrain , Japanese , Deerfield Orbimed , Instituto Butantan , Joshua Drumm , Vivalis Intercell , Tropical Disease Priority Review Voucher Program , Vaccines Announce European Partnership For Marketing , Global Communications , Drug Administration , European Commission For Valneva Inactivated , Pan American Health Organization , European Medicines Agency , Pfizer , Us Department Of Defense , European Union Member States , European Commission , European Union , Deerfield Management Company Orbimed , Coalition For Epidemic Preparedness Innovations , Euronext Paris , Chief Financial Officer , Biologics License Application , Prescription Drug User Fee Act , Epidemic Preparedness Innovations , Breakthrough Therapy , Priority Review Voucher , North America , Fast Track , Against Lyme , Outdoor Recreationists , Good Clinical Practice , United Arab , Valneva Sweden , Deerfield Management Company , European Investor , Global Investor Relations , Announces Closing , Global Offering , Announces Upsized Financing Arrangement , Funds Deerfield , Chikungunya Vaccine License Application , Priority Review , Initiates Rolling Submission , License Application , Single Shot Chikungunya Vaccine Candidate , Successfully Completes Pivotal Phase , Single Shot Chikungunya Vaccine , Reports Positive , Month Antibody Persistence Data , Announces Initiation , Adolescent Phase , Completes Enrollment , Disease Priority Review Voucher Program , Pfizer Report Six Month Antibody Persistence Data , Lyme Disease Vaccine Candidate , Valneva Initiate Phase , Pfizer Report Further Positive Phase , Including Booster Response , Valneva Issue Update , Trial Evaluating Lyme Disease Vaccine Candidate , Pfizer Enter , Equity Subscription Agreement , Update Terms , Collaboration Agreement , Fifth Disease , Prescribing Information , Medication Guide , Enterotoxigenic Escherichia , Receives Marketing Authorization , Inactivated Whole Virus , Receives Conditional Marketing Authorization , Receives Emergency Use Authorization , Confirms Amendment , Advance Purchase Agreement , Provides Clinical , Regulatory Updates , Announce European Partnership , Diese Gold Aktie , Sichern Sie , Valneva , Alneva , Eports , Ull , Ear , 022 , Esults , Rovides , Orporate , Pdates ,